Cited by 1,415Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Weber, Jeffrey S., Kähler, Katharina C., Hauschild, Axel·2012·Journal of Clinical Oncology

DOI 10.1200/jco.2012.41.6750

Open this paper in CoChat — free account

Abstract

Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)—ipilimumab and tremelimumab—have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was approved by the US Food and Drug Administration for the treatment of metastatic melanoma. We review the literature on managing the adverse effects and kinetics of tumor regression with ipilimumab and provide guidelines on their management. During treatment with these antibodies, a unique set of adverse effects may occur, called immune-related adverse events (irAEs). These include rashes, which may rarely progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mild to moderate, but occasionally also severe and persistent diarrhea. Hypophysitis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, neuropathies, and nephritis have also been reported with ipilimumab. Early recognition of irAEs and initiation of treatment are critical to reduce the risk of sequelae. Interestingly, irAEs correlated with treatment response in some studies. Unique kinetics of response have been observed with CTLA-4 blockade with at least four patterns: (1) response in baseline lesions by week 12, with no new lesions seen; (2) stable disease, followed by a slow, steady decline in total tumor burden; (3) regression of tumor after initial increase in total tumor burden; and (4) reduction in total tumor burden during or after the appearance of new lesion(s) after week 12. We provide a detailed description of irAEs and recommendations for practicing oncologists who are managing them, along with the unusual kinetics of response associated with ipilimumab therapy.

Integrity signals

Registry

Crossref · 10.1200/jco.2012.41.6750

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citation
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 5

Lebbé C, Presented at Perspectives in Melanoma XII, Scheveningen/the Hague, the Netherlands
Weber JS, 2009, J Clin Oncol, 27, 466s
Saenger YM, 2008, Cancer Immun, 8, 1
Pennock GK, 2011, Am J Clin Oncol
Yuan J, 2010, Cancer Immun, 10, 1

Sorted by citations

Items 501–600 of 999

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang, H. C., Luo, W., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0532-1 · Cited by 41
Immune checkpoint inhibitor–related luminal GI adverse events
Kröner, P. T., Mody, K., & Farraye, F. A. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.09.009 · Cited by 41
Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer
Zhou, Y., Xia, R., Xiao, H., Pu, D., Long, Y., Ding, Z., Liu, J., & Ma, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107296 · Cited by 42
Immune Toxicities and Long Remission Duration after Ipilimumab Therapy for Metastatic Melanoma: Two Illustrative Cases
Assi, H. I., & Wilson, K. S. (2013) · Current Oncology · doi:10.3747/co.20.1265 · Cited by 41
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival
Remigis, A. D., de Gruijl, T. D., Uram, J. N., Tzou, S.-C., Iwama, S., Talor, M. V., Armstrong, T. D., Santegoets, S. J. A. M., Slovin, S. F., Zheng, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28973 · Cited by 40
Histopathological aspects of cutaneous erythematous‐papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma
Perret, R. E., Josselin, N., Knol, A., Khammari, A., Cassecuel, J., Peuvrel, L., Dréno, B., & Supported by GESTIM Nantes group of cutaneous adverse events induced by anticancer drugs (2017) · International Journal of Dermatology · doi:10.1111/ijd.13540 · Cited by 40
Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures
Hickey, R., Kulik, L., Nimeiri, H. S., Kalyan, A., Kircher, S. M., Desai, K. R., Riaz, A., Lewandowski, R. J., & Salem, R. (2017) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2017.07.018 · Cited by 40
“Although the incidence of hepatoxicity is more common with combination CTLA-4 and PD-1 therapy, the incidence of grade 3/4 hepatoxicity remains less than 5% for single-agent and combination immune checkpoint inhibition (64,68,69).”
Background
Key questions about the checkpoint blockade-are microRNAs an answer?
Dragomir, M. P., Chen, B., Fu, X., & George, A. C. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0006 · Cited by 41
A Review of Immune-Mediated Adverse Events in Melanoma
Kennedy, L. B., & Salama, A. K. S. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0096-8 · Cited by 41
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer
Tamiya, A., Tamiya, M., Nakahama, K., Taniguchi, Y., Shiroyama, T., Isa, S., Inoue, T., Okishio, K., Nishino, K., Kumagai, T., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11943 · Cited by 40
Effects of periodontitis on cancer outcomes in the era of immunotherapy
Pai, S. I., Matheus, H. R., & Guastaldi, F. P. S. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00021-1 · Cited by 46
Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma
Sullivan, R. J., & Flaherty, K. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3061 · Cited by 39
Late presentation of generalised bullous pemphigoid‐like reaction in a patient treated with pembrolizumab for metastatic melanoma
Parakh, S., Nguyen, R., Opie, J. M., & Andrews, M. C. (2016) · Australasian Journal of Dermatology · doi:10.1111/ajd.12488 · Cited by 39
Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission
Yatim, N., Mateus, C., & Charles, P. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.11.008 · Cited by 39
Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors
Romanski, N. A., Holmstroem, R. B., Ellebæk, E., & Svane, I. M. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.041 · Cited by 39
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
Biewenga, M., van der Kooij, M. K., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Boers‐Sonderen, M. J., Hospers, G. A. P., Piersma, D., van Rijn, R. S., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10151-4 · Cited by 40
Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
Chieng, J. H. L., Htet, Z. W., Zhao, J. J., Tai, E. S., Tay, S. H., Huang, Y., Wong, A. S. C., & Yang, S. P. (2022) · Cancers · doi:10.3390/cancers14112687 · Cited by 40
Immunomodulation: checkpoint blockade etc.: Fig. 1.
Curry, W. T., & Lim, M. K. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov174 · Cited by 38
“Common examples of immunerelated toxicities are colitis, hypophysitis, thyroiditis, dermatitis, pancreatitis, pneumonitis, hepatitis, arthritis, nephritis, and neuropathies.(3,17,32) In making the diagnosis, timing often plays a key role in establishing a link to the various checkpoint inhibitors.”
Background
Meningoencephalitis Following Ipilimumab Administration in Metastatic Melanoma
Stein, M. K., Summers, B. B., Wong, C. A., Box, H. L., & Cleveland, K. O. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000584 · Cited by 38
Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)
Chia, P. L., & John, T. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000121 · Cited by 38
Cancer immunotherapy in patients with preexisting autoimmune disorders
Donia, M., Pedersen, M., & Svane, I. M. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0595-8 · Cited by 39
“These irAE typically developed acute or subacute, within days to weeks [32], but can in most cases be resolved with”
Background
Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases
Pushkarevskaya, A., Neuberger, U., Dimitrakopoulou‐Strauss, A., Enk, A., & Hassel, J. C. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000178 · Cited by 39
Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma
Siefker-Radtke, A. O., Apolo, A. B., Bivalacqua, T. J., Spiess, P. E., & Black, P. C. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.10.041 · Cited by 38
Cost‐effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer
Chu, J. N., Choi, J., Ostvar, S., Torchia, J. A., Reynolds, K. L., Tramontano, A. C., Gainor, J. F., Chung, D. C., Clark, J. W., & Hur, C. (2018) · Cancer · doi:10.1002/cncr.31795 · Cited by 38
“Estimates of the incidence and timing of adverse events are largely based on experience with ipilimumab alone.(38,39) We relied on data from the European Society for Medical Oncology guidelines to estimate the timing of peak ipilimumab and nivolumab toxicities and peak nivolumab toxicities.”
Method
Immune-related adverse events: A bibliometric analysis
Jiang, S., Liu, Y.-G., Zhang, L., Sang, X., Xu, Y., & Lu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096806 · Cited by 38
“published a review in 2012 that systematically described the symptoms of irAEs caused by ipilimumab and management strategies (33).”
Background
Current Perspectives on Immunotherapy
Weber, J. S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.003 · Cited by 37
Self-citation
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma
Spain, L. A., & Larkin, J. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1141195 · Cited by 37
“All-grade (%) [5,8] Grade 3 and 4 (%) [5,8] Typical time of onset (weeks) [5,8,37,38] Median time to resolution (weeks) [5,8]”
Background
Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
Minor, D. R., Bunker, S. R., & Doyle, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5095 · Cited by 37
Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma
Hughes, T. M., Klairmont, M. M., Sharfman, W. H., & Kaufman, H. L. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095401 · Cited by 37
“Any irAEs would generally emerge before the last dose of the treatment course, although hepatitis and endocrinopathies have been reported after the last dose of drug.(70) Table 2.”
Background
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
Beck, K. M., Dong, J., Geskin, L. J., Beltrani, V. P., Phelps, R. G., Carvajal, R. D., Schwartz, G. K., Saenger, Y. M., & Gartrell, R. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0123-3 · Cited by 37
“The kinetics of immunotherapy are such that responses may develop after many weeks and months of therapy, with benefits lasting even after discontinuation [20].”
Background
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses
Kwek, S. S., Kahn, J. G., Greaney, S. K., Lewis, J., Cha, E., Zhang, L., Weber, R. W., Leonard, L., Markovic, S. N., Fong, L. H., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1101204 · Cited by 35
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Koelzer, V. H., Buser, T. A., Willi, N., Rothschild, S. I., WICKI, A. N., Schiller, P. I., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0151-z · Cited by 37
“For most patients, dermatologic toxicity is the earliest detectable immune-related adverse event, with average onset at 3.6 weeks after the initiation of immunotherapy [5, 6].”
BackgroundInfluential
Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management
Hwang, S. J. E., Anforth, R., Carlos, G., & Fernández‐Peñas, P. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2016.05.019 · Cited by 38
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.012 · Cited by 37
Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
Agrawal, K., & Agrawal, N. (2019) · Case Reports in Neurological Medicine · doi:10.1155/2019/5353202 · Cited by 36
Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings
Nishida, T., Iijima, H., & Adachi, S. (2019) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v10.i2.17 · Cited by 40
Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms
Song, W., Das, M., & Chen, X. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.011 · Cited by 38
“As greater numbers of checkpoint targeting agents are entering clinical stages, irAEs are becoming a critical concern for the stakeholders in immuno-oncology drug development [54, 55].”
Background
Cardiotoxicity risk factors with immune checkpoint inhibitors
Brumberger, Z. L., Branch, M. E., Klein, M. W., Seals, A. L., Shapiro, M. D., & Vasu, S. (2022) · Cardio-Oncology · doi:10.1186/s40959-022-00130-5 · Cited by 39
“Common side effects of these medications include: colitis, dermatitis, endocrinopathies, hepatitis, and pneumonitis [6, 7].”
BackgroundResult
Ipilimumab in melanoma
Specenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1211936 · Cited by 38
Eosinophil may be a predictor of immune‐related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study
Tasaki, Y., Sugiyama, Y., Hamamoto, S., Naiki, T., Uemura, T., Yokota, K., Kawakita, D., Nakamura, M., Ogawa, R., Shimura, T., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6724 · Cited by 39
“32 In addition, irAEs may occur up to 6 months after discontinuation of ICIs, 33 and 28.8% of ICI-rechallenged patients experience the same irAEs associated with the discontinuation of ICIs.”
BackgroundInfluential
Safety of pembrolizumab for the treatment of melanoma
Martín-Liberal, J., Kordbacheh, T., & Larkin, J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1021774 · Cited by 36
Vemurafenibfor the treatment of melanoma
Jordan, E., & Kelly, C. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.737780 · Cited by 36
Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report
Carl, D. J., Grüllich, C., Hering, S., & Schabet, M. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1283-9 · Cited by 36
Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
Braschi‐Amirfarzan, M., Tirumani, S. H., Hodi, F. S., & Nishino, M. (2017) · Korean Journal of Radiology · doi:10.3348/kjr.2017.18.1.42 · Cited by 36
“Examples include new sarcoid-like distributed lymph nodes (bilateral hilar and mediastinal), which have been reported in up to 5% of patients on ICIs treatment (50, 59-62).”
Background
Immune-Related Musculoskeletal Toxicities Among Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review
Abdel-Rahman, O. M., Eltobgy, M. M., Oweira, H., Giryes, A., Tekbaş, A., & Decker, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0108 · Cited by 36
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
Majem, M., García-Martínez, E., Martinez, M., Muñoz‐Couselo, E., Rodríguez‐Abreu, D., Álvarez, R., Arance, A. M., Berrocal, A., de la Cruz‐Merino, L., & Lopez-Martin, J. A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02273-x · Cited by 36
“Managing irAEs frequently involve other specialists, such as dermatologists, gastroenterologists, neurologists, endocrinologists, and others, who should become aware of these toxicities [12].”
BackgroundInfluential
Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Abdou, Y. G., Pandey, M. R., Sarma, M., Shah, S., Baron, J. I., & Ernstoff, M. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14316 · Cited by 35
“5%) and peripheral neuropathies (<1%).(21) A number of organi-”
Background
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
von Itzstein, M. S., Gonugunta, A. S., Wang, Y., Sheffield, T. Y., Lü, R., Ali, S., Fattah, F. J., Xie, D., Cai, J. X., Xie, Y., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03151-2 · Cited by 36
Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report
Shah, S., Manzoor, S., Rothman, Y., Hagen, M. C., Pater, L. E., Golnik, K. C., Mahammedi, A., Lin, A. L., Bhabhra, R., Forbes, J. A., et al. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002024 · Cited by 36
Nanomedicine for advanced cancer immunotherapy
Diep, Y. N., Kim, T. J., Cho, H., & Lee, L. P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.004 · Cited by 35
Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials
Vardarli, I., Tan, S., Brandenburg, T., Weidemann, F., Görges, R., Herrmann, K., & Führer, D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad670 · Cited by 40
New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
Miserocchi, E., Cimminiello, C., Mazzola, M., Russo, V. E. A., & Modorati, G. M. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.10.010 · Cited by 35
Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
Bidnur, S., Savdie, R., & Black, P. C. (2016) · Bladder Cancer · doi:10.3233/blc-150026 · Cited by 36
“This toxicity profile is in contrast to reported tolerability of CTLA-4 blockade, which appears to be associated with higher grade AE characterized predominantly by various grades of dermatitis and colitis [58].”
Result
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Jung, M., Lee, J., Kim, T. M., Lee, D. H., Kang, J., Oh, S. Y., Lee, S. J., & Shin, S. J. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.024 · Cited by 35
Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma
Matsubara, T., Nishida, T., Higaki, Y., Tomita, R., Shimakoshi, H., Shimoda, A., Osugi, N., Sugimoto, A., Takahashi, K., Nakamatsu, D., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9851-17 · Cited by 35
“In a pooled analysis of nivolumab-treated patients, the onset of hepatitis was found to occur between 6 and 14 weeks after treatment (15).”
Background
Liver Toxicity with Cancer Checkpoint Inhibitor Therapy
Nadeau, B. A., Fecher, L. A., Owens, S. R., & Razumilava, N. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1667358 · Cited by 36
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
Ruggiero, R., Fraenza, F., Scavone, C., di Mauro, G., Piscitelli, R., Mascolo, A., Ferrajolo, C., Rafaniello, C., Sportiello, L., Rossi, F., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00830 · Cited by 35
“CTLA-4 is involved in proximal steps, while PD-1 takes part in later stages of the immune response (Weber et al., 2012; Varricchi et al., 2017).”
Background
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis
Panneerselvam, K., Amin, R. N., Wei, D., Tan, D., Lum, P. J., Zhang, H. C., Richards, D. M., Altan, M., Grivas, P. D., Thompson, J. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7675 · Cited by 35
Recognizing and managing on toxicities in cancer immunotherapy
Liu, Y., Hui-fang, Y., Dong, S., Zhong, Y., & Hu, S. (2017) · Tumor Biology · doi:10.1177/1010428317694542 · Cited by 37
Immune Checkpoint Inhibitors in Lung Cancer: Past, Present and Future
Seetharamu, N., Budman, D. R., & Sullivan, K. M. (2016) · Future Oncology · doi:10.2217/fon.16.20 · Cited by 34
A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy
Kottschade, L. A., Brys, A. K., Peikert, T., Ryder, M. M., Raffals, L. E., Brewer, J. D., Mosca, P. J., & Markovic, S. N. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000273 · Cited by 34
Unintended Immunological Consequences of Biologic Therapy
Henrickson, S. E., Ruffner, M. A., & Kwan, M. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0624-7 · Cited by 36
Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study
Weide, B., Martens, A., Wistuba‐Hamprecht, K., Zelba, H., Maier, L., Lipp, H., Klumpp, B. D., Soffel, D., Eigentler, T., & Garbe, C. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1944-0 · Cited by 34
Approach and management of checkpoint inhibitor-related immune hepatitis
Sanjeevaiah, A. R., Kerr, T. A., & Beg, M. S. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.08.14 · Cited by 34
“Hepatotoxicity can occur at any time after treatment but is most commonly seen after 6–12 weeks of the therapy (10).”
Background
Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report
Takeno, A., Yamamoto, M., Morita, M., Tanaka, S., Kanazawa, I., Yamauchi, M., Kaneko, S., & Sugimoto, T. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0335-x · Cited by 34
Adverse cutaneous reactions to chemotherapeutic drugs
Haynes, D., & Ortega‐Loayza, A. G. (2020) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2020.06.007 · Cited by 35
A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
Henderson, A. D., & Thomas, D. A. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000081 · Cited by 34
Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease
Thomas, A. S., Hanauer, S. B., & Wang, Y. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.004 · Cited by 32
Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review
Kopecký, J., Trojanova, P., ek, O. K., & Kopecký, O. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu222 · Cited by 33
Case 21-2013
Sullivan, R. J., Lawrence, D. P., Wargo, J. A., Oh, K. S., Gonzalez, R. G., & Piris, A. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1302332 · Cited by 34
Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician
Lomax, A. J., & McNeil, C. M. (2017) · Emergency Medicine Australasia · doi:10.1111/1742-6723.12718 · Cited by 33
“Symptomatic patients require timely treatment with steroids (and ongoing physiological steroid replacement) and then replacement of any other relevant pituitary hormone axis affected.(14,15) Adrenal crisis might ensue and urgent i.”
BackgroundInfluential
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Afzal, M. Z., Mabaera, R., & Shirai, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0322-1 · Cited by 33
Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer
Manz, S., Losa, M., Fritsch, R., & Scharl, M. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211002018 · Cited by 36
Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy
Suzuki, S., Suzuki, S., Shibata, K., Shibata, K., Kikkawa, F., Kikkawa, F., Nakatsura, T., & Nakatsura, T. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27217 · Cited by 33
Cutaneous toxicities of new treatments for melanoma
Boada, A., Carrera, C., Segura, S., Collgros, H., Pasquali, P., Bodet, D., Puig, S., & Malvehy, J. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1891-7 · Cited by 33
Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
Allen, K. J. H., Jiao, R., Malo, M. E., Frank, C., Fisher, D. R., Rickles, D. J., & Dadachova, E. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070348 · Cited by 33
“Unfortunately, only a small amount of patients respond well to the current immune therapies, coupled with very serious side effects and the large cost of these treatments [9,10] there is still a high demand for additional approaches to combat metastatic melanoma that can either stand alone or as a combination therapeu…”
Background
Immune checkpoint inhibitors and acute kidney injury
Zhou, P., Gao, Y., Kong, Z., Wang, J., Si, S., Han, W., Li, J., Lv, Z., & Wang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353339 · Cited by 33
“As examples, the common dermatitis usually develops within 4 weeks (44, 66, 67) and colitis within 6 weeks after ICIs treatment (43).”
BackgroundInfluential
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark
Kroemer, G., & Galluzzi, L. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1058037 · Cited by 32
Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma
Buchbinder, E. I., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.003 · Cited by 32
Expert opinion on pituitary complications in immunotherapy
Briet, C., Albarel, F., Kuhn, E., Merlen, E., Chanson, P., & Cortet, C. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.008 · Cited by 32
Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma
Bianchini, F., Portioli, E., Ferlenghi, F., Vacondio, F., Andreucci, E., Biagioni, A., Ruzzolini, J., Peppicelli, S., Lulli, M., Calorini, L., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.12.021 · Cited by 32
“), many concerns still exist dealing with the observed overall toxicity [19,20], the effective dosing regimens and, above all, the insurgence of resistance mechanisms leading to tumor relapse and progression to a metastatic disease with incredibly aggressive features [21].”
Background
Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors
Kamińska‐Winciorek, G., Cybulska-Stopa, B., Lugowska, I. A., Ziobro, M., & Rutkowski, P. L. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2018.80272 · Cited by 32
Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy
Kanjanapan, Y., & Yip, D. (2020) · Cancer Medicine · doi:10.1002/cam4.3532 · Cited by 32
“Treatment duration Cycles received 7 (1-98) 5 (1-71) 0.”
Background
The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Sheikholeslami, S. A., Salari, S., & Bashash, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103160 · Cited by 34
NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy
Yoshihama, S., Cho, S., Yeung, J., Pan, X., Lizee, G. A., Konganti, K., Johnson, V. E., & Kobayashi, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82729-9 · Cited by 32
Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
Cunningham, M. E., Iafolla, M. A. J., Kanjanapan, Y., Cerocchi, O., Butler, M. O., Siu, L. L., Bedard, P. L., Ross, K., Hansen, B. E., Spreafico, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253070 · Cited by 33
“6%) was comparable with other published data [1, 4, 15, 16].”
Result
The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients
Moschen, A. R., Sammy, Y., Marjenberg, Z. R., Heptinstall, A. B., Pooley, N., & Marczewska, A. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01267-3 · Cited by 35
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Nikoo, M., Rabiee, F., Mohebbi, H., Eghbalifard, N., Rajabi, H., Yazdani, Y., Sakhaei, D., Khosravifarsani, M., & Akhavan‐Sigari, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109881 · Cited by 33
The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors
Demlová, R., Valík, D., Obermannova, R. L., & Dubská, L. Z. (2016) · Physiological Research · doi:10.33549/physiolres.933525 · Cited by 32
Biologic response modifiers: Indications, implications, and insights
Davis, B. P., & Ballas, Z. K. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.02.013 · Cited by 31
The 100 top-cited studies in cancer immunotherapy
Zhang, Y., Quan, L., & Du, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1623234 · Cited by 31
“Management of immune-related adverse events and kinetics of response with ipilimumab [94] Journal of Clinical Oncology Review 642 2012 7 22614989”
Background
Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report
Hardy, T., Yin, M., Chavez, J. A., Ivanov, I., Chen, W., Nádasdy, T., & Brodsky, S. V. (2020) · Cardiovascular Pathology · doi:10.1016/j.carpath.2020.107202 · Cited by 31
Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis
Hasson, S. P., Salwen, B., Sivan, A., Shamai, S., Geva, R., Merimsky, O., Raphael, A., Shmilovich, H., Moshkovits, Y., Kapusta, L., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01648-3 · Cited by 32
“Some of the commonly characterized toxicities are rash, diarrhea, colitis, and hypophysitis [10], however, myocarditis was not identified as an ICI-mediated adverse event in pivotal trials [11–13].”
Background
Diagnosis and management of immune‐related adverse effects of immune checkpoint therapy in the emergency department
Yeung, S. J., Qdaisat, A. Z., Chaftari, P. S., Lipe, D. N., Merlin, J., Rajha, E., Wechsler, A. H., Sandoval, M., Viets-Upchurch, J. M., Al‐Breiki, A., et al. (2020) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12209 · Cited by 29
Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors
Burns, E. A., Muhsen, I. N., Anand, K., Xu, J., Umoru, G., Arain, A., & Abdelrahim, M. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000358 · Cited by 31
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Dearden, H. C., Au, L., Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Cuvietto, M., Khoo, C. C. H., Atkinson, V. G., Lo, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.045 · Cited by 31
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982026 · Cited by 32
Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
Bourke, J., O'Sullivan, M. D., & Khattak, M. A. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00586 · Cited by 31
Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper
Bastiaannet, E., Battisti, N. M. L., Loh, K. P., de Glas, N. A., Soto‐Pérez‐de‐Celis, E., Baldini, C., Kapiteijn, E., & Lichtman, S. M. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.06.009 · Cited by 31
“Approximately 20–30% of the adverse events were grade 3–4 [32].”
Background

Authors: Weber, J. S., Kähler, K. C., & Hauschild, A.
Affiliations: Moffitt Cancer Center (US)
ORCID: Weber, Jeffrey S.
Kähler, Katharina C.
Hauschild, Axel
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2012-07-20
Volume: 30
Issue: 21
Pages: 2691-2697
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2012.41.6750
OpenAlex: W2109653150
Cited by: 1,415
References: 33
Citations by year: 2026: 24 · 2025: 35 · 2024: 59 · 2023: 79 · 2022: 84 · 2021: 117 · 2020: 129 · 2019: 123 · 2018: 146 · 2017: 153 · 2016: 152 · 2015: 145 · 2014: 94 · 2013: 65 · 2012: 9
FWCI: 10.34
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: ipilimumab, immune-related adverse events, CTLA-4 blockade, metastatic melanoma, immune checkpoint inhibitors, toxic epidermal necrolysis, colitis, hypophysitis, hepatitis, iridocyclitis, neuropathy, nephritis, adverse event management
MeSH terms: Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Colitis, Drug Eruptions, Diarrhea, Humans, Liver, Lymphatic Diseases, Melanoma, Mucous Membrane, Pancreatitis, Peripheral Nervous System Diseases, Pituitary Gland, Skin, Skin Neoplasms, Stevens-Johnson Syndrome, Uveitis, Scleritis, Chemical and Drug Induced Liver Injury, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks